RAAV9-mediated Supplementation of MiR-29b Improve Angiotensin-II Induced Renal Fibrosis in Mice
Overview
Molecular Biology
Authors
Affiliations
Background: Renin-angiotensin-aldosterone system activation is the critical factor in renal remodeling and dysfunction. Our previous study suggested that miR-29b may attenuate AngII-induced renal intestinal fibrosis in vitro. In the present study, we aimed to determine whether recombinant rAAV9-mediated miR-29b delivery protects against AngII-induced renal fibrosis and dysfunction.
Method: Mice were treated with AngII via osmotic mini-pumps, or phosphate-buffered saline. rAAV9 vectors were produced using the rBac-based system in SF9 cells. rAAV9-miR-29b or rAAV9-control-miR was injected into the kidneys of mice subjected to the model of AngII infusion. The role of miR-29b in renal fibrosis was assessed using quantitative polymerase chain reaction, western blot, and histology.
Results: In AngII-induced fibrotic kidney tissue, miR-29b expression was downregulated. rAAV9-miR-29b delivery significantly reversed renal injury as indicated by decreased serum creatinine and injury related gene expression in AngII-infused mice. Regarding organ remodeling, tubulointerstitial fibrosis and deposition of extracellular matrix components such as collagen type I and type III were significantly decreased in renal tissue from mice delivered rAAV9-miR-29b.
Conclusion: Our results demonstrate great potential for use of rAAV9 as an applicable vector for delivery of miR-29b as an antifibrogenic factor for treatment of tubulointerstitial fibrosis-induced renal injury.
Zhu J, Li L, Luan Y, Zhang Z, Wang Y, Xu Z Dose Response. 2024; 22(4):15593258241298045.
PMID: 39506979 PMC: 11539081. DOI: 10.1177/15593258241298045.
Rajabi S, Saberi S, Najafipour H, Askaripour M, Rajizadeh M, Shahraki S Mol Biol Rep. 2024; 51(1):137.
PMID: 38236310 DOI: 10.1007/s11033-023-09127-4.
Chen Y, Hsu C, Tsai S, Chen C Int J Mol Sci. 2022; 23(20).
PMID: 36293110 PMC: 9603156. DOI: 10.3390/ijms232012253.
Cai Y, Feng Z, Jia Q, Guo J, Zhang P, Zhao Q Front Pharmacol. 2022; 12:801094.
PMID: 35222012 PMC: 8866973. DOI: 10.3389/fphar.2021.801094.